The possible reason was that the population included in our study had a higher level of PD-L1 expression than other studies, and NSCLC patients with PD-L1 TPS ≥ 50% seemed to benefit from immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.